OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

Clinical trial NCT04757610 · TERMINATED

Trial details

NCT number: NCT04757610
Sponsor: Opthea Limited
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Neovascular Age-related Macular Degeneration

Start date: 2021-03-12
Primary completion: 2025-03-31
Enrollment: 986

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.